The director of the Chinese epidemic control center, Zhao Fu, said that the possibility of using other vaccines by adopting other techniques is being evaluated to provide high immunity.
This is the first Chinese admission of the limited effectiveness of the Chinese vaccine against Corona.
Gao explained that taking steps to “improve” the vaccination process by changing the number of doses and the time period between them is a “sure” solution to potency problems.
Another official at the center said that the vaccines that use “RNA” technology, on which Pfizer and Moderna have relied, have entered the clinical trial stages in China, but he did not provide any details about their use.
China has made 4 domestic vaccines that have been approved for public use, and an official said Saturday that the country will likely produce 3 million doses by the end of the year.
In the context of vaccines, an Israeli study concluded that the mutated Corona virus strain discovered in South Africa is capable of somehow penetrating the Pfizer-BioNTech vaccine, despite the low prevalence of the strain inside Israel.
The study showed that the prevalence of the strain among patients who received two doses of the Pfizer-Bionic vaccine was 8 times higher among unvaccinated patients.
The researchers said that this indicates that the vaccine is less effective with the South African strain compared to the original strain of the virus, as well as the strain discovered in Britain.
The researchers cautioned, however, that the study was conducted on a small group of individuals infected with the strain due to its scarcity in Israel.